tbuckley/cabot-search huggingface dataset:
The Milroy Lectures ON INDUSTRIAL ANTHRAX: Delivered before the Royal College of Physicians of London
Authors: T. M. Legge
Journal: BMJ (1905)

UNDER the Factory and Workshop Act all cases of anthrax contracted in connexion with various industries have to be reported to the Home Office, and I intend to deal with the cases-261 in number-which were thus notified during the six years I899-I904 inclusive.These are classified in the following table : Industry.Males.Females.,
New insights into diagnosis and therapeutic options for proliferative hepatoblastoma
Authors: Katarzyna B. Hooks, Jérôme Audoux, Helena Fazli, Sarah Lesjean, Tony Ernault, Nathalie Dugot‐Senant, Thierry Leste‐Lasserre, Martin Hagedorn, Benoit Rousseau, Coralie Danet, Sophie Branchereau, Laurence Brugières, Sophie Taque, Catherine Guettier, Monique Fabre, Anne Rullier, Marie‐Annick Buendia, Thérèse Commes, Christophe F. Grosset, Anne‐Aurélie Raymond
Journal: Hepatology (2017)

Surgery and cisplatin‐based treatment of hepatoblastoma (HB) currently guarantee the survival of 70%‐80% of patients. However, some important challenges remain in diagnosing high‐risk tumors and identifying relevant targetable pathways offering new therapeutic avenues. Previously, two molecular subclasses of HB tumors have been described, C1 and C2, with C2 being the subgroup with the poorest prognosis, a more advanced tumor stage, and the worst overall survival rate. An associated 16‐gene signature to discriminate the two tumoral subgroups was proposed, but it has not been transferred into clinical routine. To address these issues, we performed RNA sequencing of 25 tumors and matched normal liver samples from patients. The transcript profiling separated HB into three distinct subgroups named C1, C2A, and C2B, identifiable by a concise four‐gene signature: hydroxysteroid 17‐beta dehydrogenase 6, integrin alpha 6, topoisomerase 2‐alpha, and vimentin, with topoisomerase 2‐alpha being characteristic for the proliferative C2A tumors. Differential expression of these genes was confirmed by quantitative RT‐PCR on an expanded cohort and by immunohistochemistry. We also revealed significant overexpression of genes involved in the Fanconi anemia (FA) pathway in the C2A subgroup. We then investigated the ability of several described FA inhibitors to block growth of HB cells in vitro and in vivo. We demonstrated that bortezomib, a Food and Drug Administration–approved proteasome inhibitor, strongly impairs the proliferation and survival of HB cell lines in vitro, blocks FA pathway–associated double‐strand DNA repair, and significantly impedes HB growth in vivo. Conclusion: The highly proliferating C2A subtype is characterized by topoisomerase 2‐alpha gene up‐regulation and FA pathway activation, and the HB therapeutic arsenal could include bortezomib for the treatment of patients with the most aggressive tumors. (Hepatology 2018;68:89‐102).
P3.02a-018 Efficacy of Pemetrexed Based Chemotherapy Compared with Non-Pemetrexed Based Chemotherapy in Advanced, ALK-Positive NSCLC
Authors: Jaemin Jo, Se Hyun Kim, Yu Jung Kim, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Jong Seok Lee
Journal: Journal of Thoracic Oncology (2017)
ESGE-ESGENA technical specification for process validation and routine testing of endoscope reprocessing in washer-disinfectors according to EN ISO 15883, parts 1, 4, and ISO/TS 15883-5
Authors: Ulrike Beilenhoff, Holger Biering, Reinhard Blum, Jadranka Brljak, Monica Cimbro, Jean-Marc Dumonceau, Cesare Hassan, Michael Jung, Christiane Neumann, Michael Pietsch, Lionel Pineau, Thierry Ponchon, Stanislav Rejchrt, Jean-François Rey, Verona Schmidt, Jayne Tillett, Jeanin van Hooft
Journal: Endoscopy (2017)

1 Prerequisites. The clinical service provider should obtain confirmation from the endoscope washer-disinfector (EWD) manufacturer that all endoscopes intended to be used can be reprocessed in the EWD. 2 Installation qualification. This can be performed by different parties but national guidelines should define who has the responsibilities, taking into account legal requirements. 3 Operational qualification. This should include parametric tests to verify that the EWD is working according to its specifications. 4 Performance qualification. Testing of cleaning performance, microbiological testing of routinely used endoscopes, and the quality of the final rinse water should be considered in all local guidelines. The extent of these tests depends on local requirements. According to the results of type testing performed during EWD development, other parameters can be tested if local regulatory authorities accept this. Chemical residues on endoscope surfaces should be searched for, if acceptable test methods are available. 5 Routine inspections. National guidelines should consider both technical and performance criteria. Individual risk analyses performed in the validation and requalification processes are helpful for defining appropriate test frequencies for routine inspections.
Abstract 18113: Persistent High Blood Urea Nitrogen Level is Associated With Increased Cardiovascular Mortality in Acute Heart Failure Patients
Authors: Kentaro Jujo, Yusuke Tanigaito, Yuichiro Minami, Ayano Yoshida, Yasuhiro Kikuchi, Shintaro Haruki, Kensuke Shimazaki, Ryosuke Itani, Hiroyuki Arashi, Eiji Shibahashi, Junichi Yamaguchi, Hiroshi Ogawa, Nobuhisa Hagiwara
Journal: Circulation (2016)

Introduction: Recent clinical trials and observations demonstrated in patients with congestive heart failure (CHF) that high blood urea nitrogen (BUN) on admission was associated with poor cardiova...
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Authors: Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, Song-Tao Xu, Lin Wu, Yi Shen, Yong-Yu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Ke Fei, Xiao-Fei Li, Jian Li, Cheng Huang, Zhi-Dong Liu, Shun Xu, Ke-Neng Chen, Shi-Dong Xu, Lun-Xu Liu, Ping Yu, Bu-Hai Wang, Hai-Tao Ma, Hong-Hong Yan, Xue-Ning Yang, Qing Zhou, Yi-Long Wu, Yi-Long Wu, Qun Wang, Wei-Min Mao, Lin Wu, Yi Shen, Yong-Yu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Ke Fei, Xiao-Fei Li, Jian Li, Cheng Huang, Zhi-Dong Liu, Shun Xu, Ke-Neng Chen, Shi-Dong Xu, Lun-Xu Liu, Ping Yu, Bu-Hai Wang, Hai-Tao Ma, Si-Yu Wang, Jian Hu, Wei Liu, Wei Li, Jian-Hua Shi
Journal: The Lancet Oncology (2017)
Abstract 21054: Hematopoietic Factors Are Sufficient to Increase AF in Aged, Atherosclerotic Mice
Authors: Roberto Ramos-Mondragon, Daniel Tyrrell, Gudalupe Guerrero-Serna, Hector Valdivia, Jose Jalife, Daniel Goldstein
Journal: Circulation (2017)

Rationale: Aging is a strong risk factor for atrial fibrillation (AF), the most common sustained arrhythmia in the clinical practice. Atrial inflammation correlates with increased AF susceptibility but whether chronic age-related inflammation that occurs with atherosclerosis contributes to AF is unknown. Hypothesis: Hematopoietic factors contribute to AF inducibility in aged atherosclerotic mice. Methods: We used burst electrical stimulation (tachypacing) of the right atrium to test susceptibility to AF in-vivo in young and aged atherosclerotic, low density lipoprotein receptor knockout (C57BL/6 Ldlr -/- ) mice, and young and old wildtype (C57BL/6 WT) mice. We also determined the role of the stroma vs. the hematopoietic system, by creating bone marrow chimeras in which aged or young Ldlr -/- mice were transplanted with age-matched or mismatched bone Ldlr -/- bone marrow. We used whole-cell patch-clamping investigate atrial sodium currents. Confocal microscopy and patch-clamping in current clamp mode was used to simultaneously record action potentials and Ca 2+ transients. Results: Upon atrial tachypacing, aged atherosclerotic mice underwent longer and more frequent AF episodes than young (incidence, 0.47±0.09 vs 0.12±0.02 episodes/attempts; p&lt;0.05 ) and aged WT mice (0.47±0.09 vs 0.16±0.07 episodes/attempts; p&lt;0.05 ). Importantly, young-to-old bone marrow chimeric mice exhibited reduced AF incidence (0.23 ± 0.05 episodes/attempts), whereas old-to-young chimeric mice exhibited increased AF incidence (0.45 ± 0.08 episodes/attempts). Atrial myocytes from aged atherosclerotic mice presented a 50% reduction in the cardiac inward sodium current (I Na ). Moreover, compared to young, aged atherosclerotic mice showed prolonged action potential duration (APD90: 34.0±5.0 ms vs 48.1±7.0ms; p&lt;0.05), post-pacing spontaneous calcium releases (25% vs 81.8%; p&lt;0.05) and triggered activity (0% vs 27.2 %; p&lt;0.05). Conclusions: Aged atherosclerotic prone mice are susceptible to AF induction. Hematopoietic factors are sufficient to increase AF propensity with aging in the atherosclerotic host possibly by causing electrophysiological remodeling and intracellular Ca 2+ handling abnormalities.
Abstract 15629: Superior Myocardial Protection With Adenosine - Triphosphate - Sensitive Potassium Channel Opener Diazoxide in a Novel Mouse Langendorff Model
Authors: Carol Makepeace, Evelyn Kanter, Richard Schuessler, Colin Nichols, Jennifer Lawton
Journal: Circulation (2016)

Introduction: Adenosine triphosphate - sensitive potassium (KATP) channel openers are cardioprotective via an unknown mechanism. Mouse models allow genetic manipulation of KATP channel components f...
A man with knee pain after a fall
Authors: Tobenna J Oputa, Ronnie Davies
Journal: BMJ (2017)

A 47 year old man presented with a painful swollen right knee after a fall down stairs. On examination, his right knee was swollen, and there was infrapatellar tenderness, a palpable defect inferior to the patella, and a large effusion on palpation. He was unable to raise his leg or extend his knee. A radiograph of the knee was taken (fig 1). What sign can be seen on this radiograph and what diagnosis is it suggestive of?



Fig 1 
Lateral radiograph of the right knee



### Short answer

Patella alta (high riding patella) suggestive of a patellar tendon rupture.

### Discussion

Patellar tendon rupture has an annual incidence of 0.68% …
Pharmacologic Treatment of Seasonal Allergic Rhinitis: Synopsis of Guidance From the 2017 Joint Task Force on Practice Parameters
Authors: Dana V. Wallace, Mark S. Dykewicz, John Oppenheimer, Jay M. Portnoy, David M. Lang
Journal: Annals of Internal Medicine (2017)

Description: The Joint Task Force on Practice Parameters, which comprises representatives of the American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI), formed a workgroup to review evidence and provide guidance to health care providers on the initial pharmacologic treatment of seasonal allergic rhinitis in patients aged 12 years or older. Methods: To update a prior systematic review, the workgroup searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from 18 July 2012 to 29 July 2016 to identify studies that addressed efficacy and adverse effects of single or combination pharmacotherapy for seasonal allergic rhinitis. In conjunction with the Joint Task Force, the workgroup reviewed the evidence and developed recommendations about initial treatment approaches by using the Grading of Recommendations Assessment, Development and Evaluation approach. Members of the AAAAI, the ACAAI, and the general public provided feedback on the draft document, which the Joint Task Force reviewed before finalizing the guideline. Recommendation 1: For initial treatment of seasonal allergic rhinitis in persons aged 12 years or older, routinely prescribe monotherapy with an intranasal corticosteroid rather than an intranasal corticosteroid in combination with an oral antihistamine. (Strong recommendation) Recommendation 2: For initial treatment of seasonal allergic rhinitis in persons aged 15 years or older, recommend an intranasal corticosteroid over a leukotriene receptor antagonist. (Strong recommendation) Recommendation 3: For treatment of moderate to severe seasonal allergic rhinitis in persons aged 12 years or older, the clinician may recommend the combination of an intranasal corticosteroid and an intranasal antihistamine for initial treatment. (Weak recommendation)
Addressing the Causality Gap in Human Psychiatric Neuroscience
Authors: Amit Etkin
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Abstract 20933: Regulation of Hypoxia Induced Cardiac Cell Death by the Intrinsic Circadian Clock
Authors: Lorrie A Kirshenbaum, Inna Rabinovich-Nikitin, Hongying Gang, Victoria Margulets, Floribeth Aguilar
Journal: Circulation (2017)

Circadian rhythms play a fundamental role in cell metabolism and tissue homeostasis and are influenced by the diurnal oscillation of cellular circadian clock genes. Zeitgebers influence the activation of the circadian rhythm by serving as molecular switches for the intrinsic cellular clock. Herein, we provide new evidence that hypoxia is a Zietgeber for the circadian rhythm and regulator of clock gene expression in cardiac myocytes. We further show that clock gene regulation promotes survival of cardiac myocytes by a mechanism that bi-directionally influences the inducible death protein Bnip3. Cardiac myocytes exhibited phasic oscillations in clock gene expression under basal conditions. Interestingly, in contrast to control cells, a marked time dependent decline in clock gene transcription was observed in cardiac myocytes subjected to hypoxia with maximal decline occurring at 18hrs. This coincided with a reciprocal increase in the expression of the mitochondrial autophagy protein Bnip3 and cell death. Given that Bnip3 is transcriptionally repressed under basal conditions, we reasoned that clock may promote cell survival by negatively regulating Bnip3 gene transcription. While Bnip3 transcription was markedly increased in cardiac myocytes subjected to hypoxia, gain of function of clock suppressed Bnip3 gene activation and cell death of cardiac myocytes. Hence, the findings of the present study provide the first direct evidence that hypoxia is a circadian Zeitgeber for circadian rhythm in cardiac myocytes. We further show that circadian protein Clock regulates cell survival during hypoxic injury by a mechanism that involves the transcriptional repression of Bnip3.
A landscape of germ line mutations in a cohort of inherited bone marrow failure patients
Authors: Olivier Bluteau, Marie Sebert, Thierry Leblanc, Régis Peffault de Latour, Samuel Quentin, Elodie Lainey, Lucie Hernandez, Jean-Hugues Dalle, Flore Sicre de Fontbrune, Etienne Lengline, Raphael Itzykson, Emmanuelle Clappier, Nicolas Boissel, Nadia Vasquez, Mélanie Da Costa, Julien Masliah-Planchon, Wendy Cuccuini, Anna Raimbault, Louis De Jaegere, Lionel Adès, Pierre Fenaux, Sébastien Maury, Claudine Schmitt, Marc Muller, Carine Domenech, Nicolas Blin, Bénédicte Bruno, Isabelle Pellier, Mathilde Hunault, Stéphane Blanche, Arnaud Petit, Guy Leverger, Gérard Michel, Yves Bertrand, André Baruchel, Gérard Socié, Jean Soulier
Journal: Blood (2017)
Letter by Jin-shan and Xue-bin Regarding Article, “Impact of the Clinical Frailty Scale on Outcomes After Transcatheter Aortic Valve Replacement”
Authors: He Jin-shan, Li Xue-bin
Journal: Circulation (2017)

We read with great interest the article by Shimura et al 1 about the prognostic impact of the Clinical Frailty Scale (CFS) on outcomes after transcatheter aortic valve replacement, which indicates that in addition to reflecting the degree of frailty and showing significant correlation with body mass index, albumin, gait speed, and grip strength, the CFS is a useful marker for predicting late mortality in an elderly transcatheter aortic valve replacement cohort.Attracted by the simple and useful characteristic of this tool, we have several suggestions for it.First, the CFS is a semiquantitative tool that provides a global score ranging from 1 (very fit) to 9 (terminally ill) to reflect the following domains: disability for basic and instrumental activities of daily living, mobility, activity, energy, and disease-related symptoms. 2Higher CFS scores are associated with slightly older age, a greater proportion of women, higher New York Heart Association class and brain natriuretic peptide level, lower serum albumin and hemoglobin, and slower average gait speed. 1 CFS is a comprehensive marker.It is the combination of patients' age, sex, body mass index, albumin, brain natriuretic peptide level, and heart function; besides, in comparison with them, it is more powerful than any of the indicators mentioned above to predict the outcomes after transcatheter aortic valve replacement.With the development of laboratory and imaging tests, we rely a lot on these tests to assess patients' status before surgeries; now we are trying to come back to the original method and evaluate the patients' body functions integrally instead of checking each system separately.CFS is a good model of this approach, which proved more effective to predict the prognosis with less effort.Second, CFS is a useful marker for predicting late mortality in an elderly transcatheter aortic valve replacement cohort, but its use should not be limited to this field.CFS is an excellent marker of the whole body's function status, which is superior to any isolated test.We hope to extend the use of this tool to other surgeries for older people; it is semiquantitative and simple, and it can be easily conducted by nongeriatricians.It will be easy to promote its utility in the evaluation of perioperative patients in other fields.We hope to achieve results similar to those reported in this article; thus, CFS can help more people than just those who undergo transcatheter aortic valve replacement!
Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab
Authors: R.B. Warren, A. Brnabic, D. Saure, R.G. Langley, K. See, J.J. Wu, A. Schacht, L. Mallbris, A. Nast
Journal: British Journal of Dermatology (2017)

Head‐to‐head randomized studies comparing ixekizumab and secukinumab in the treatment of psoriasis are not available. To assess efficacy and quality of life using matching‐adjusted indirect comparisons for treatment with ixekizumab vs. secukinumab. Psoriasis Area and Severity Index (PASI) improvement of at least 75%, 90% and 100% and Dermatology Life Quality Index (DLQI) 0/1 response rates for approved dosages of ixekizumab (160 mg at Week 0, then 80 mg every two weeks for the first 12 weeks) and secukinumab (300 mg at Weeks 0, 1, 2, 3 and 4, then 300 mg every 4 weeks) treatment were compared using data from active (etanercept and ustekinumab) and placebo‐controlled studies. Comparisons were made using the Bucher (BU) method and two modified versions of the Signorovitch (SG) method (SG total and SG separate). Subsequently, results based on active treatment common comparators were combined using generic inverse‐variance meta‐analysis. In the meta‐analysis of studies with active comparators, PASI 90 response rates were 12·7% [95% confidence interval (CI) 5·5–19·8, P =0·0005], 10·0% (95% CI 2·1–18·0, P =0·01) and 11·2% (95% CI 3·2–19·1, P =0·006) higher and PASI 100 response rates were 11·7% (95% CI 5·9–17·5, P <0·001), 12·7% (95% CI 6·0–19·4, P <0·001) and 13·1% (95% CI 6·3–19·9, P <0·001) higher for ixekizumab compared with secukinumab using BU, SG total and SG separate methods. PASI 75 results were comparable when SG methods were used and favoured ixekizumab when the BU method was used. Week 12 DLQI 0/1 response rates did not differ significantly. Ixekizumab had higher PASI 90 and PASI 100 responses at week 12 compared with secukinumab using adjusted indirect comparisons.
Autonomous development and learning in artificial intelligence and robotics: Scaling up deep learning to human-like learning
Authors: Pierre-Yves Oudeyer
Journal: Behavioral and Brain Sciences (2017)

Abstract Autonomous lifelong development and learning are fundamental capabilities of humans, differentiating them from current deep learning systems. However, other branches of artificial intelligence have designed crucial ingredients towards autonomous learning: curiosity and intrinsic motivation, social learning and natural interaction with peers, and embodiment. These mechanisms guide exploration and autonomous choice of goals, and integrating them with deep learning opens stimulating perspectives.
A Transferrin-Conjugated Hollow Nanoplatform for Redox-Controlled and Targeted Chemotherapy of Tumor with Reduced Inflammatory Reactions
Authors: Jun Zhou, Menghuan Li, Wei Qi Lim, Zhong Luo, Soo Zeng Fiona Phua, Runlan Huo, Liqi Li, Ke Li, Liangliang Dai, Junjie Liu, Kaiyong Cai, Yanli Zhao
Journal: Theranostics (2017)

In this study, we report the design, development and evaluation of a hollow drug delivery nanoplatform for cancer therapy
Evaluation of eribulin and bevacizumab for the real world treatment of recurrent breast cancer
Authors: M. Earashi, K. Matsui, K. Maeda, W. Fukushima, K. Shimada, T. Shimizu, Z. Nozaki, Y. Tanada, K. Oyama, T. Nagata, A. Tsuneda, A. Yoshikawa, T. Yoshida, K. Kiyohara, K. Iwata, T. Ii
Journal: Annals of Oncology (2017)
Salm-Net : un réseau européen de surveillance des salmonelloses humaines
Authors: I. S.T. Fisher
Journal: Eurosurveillance (1995)

Le programme Salm-Net a pour but la prevention des salmonelloses dansl'UE en renforcant leur surveillance internationale a partirdes laboratoires et en creant une base de donneeseuropeenne disponible a tous les participants. Salm-Net estfinance par le programme BIOMED 1 de la DG XII de la CommissionEuropeenne. Le reseau est compose de microbiologistes etd'epidemiologistes de 14 pays, responsables de lasurveillance des salmonelloses a un niveau national. Salm-Net a aussipour but d'harmoniser en Europe les procedures de serotypagedes phages de Salmonella enteritidis, S. typhimurium, et S. virchow.
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Authors: Paul M Ridker, Jean G MacFadyen, Brendan M Everett, Peter Libby, Tom Thuren, Robert J Glynn, Paul M Ridker, Jean G MacFadyen, Brendan M Everett, Peter Libby, Tom Thuren, Robert J Glynn, John Kastelein, Wolfgang Koenig, Jacques Genest, Alberto Lorenzatti, John Varigos, Peter Siostrzonek, Peter Sinnaeve, Francisco Fonseca, Jose Nicolau, Nina Gotcheva, Huo Yong, Miguel Urina-Triana, Davor Milicic, Renata Cifkova, Riina Vettus, Stephan D Anker, Athanasios J Manolis, Fernando Wyss, Tamas Forster, Axel Sigurdsson, Prem Pais, Alessandro Fucili, Hisao Ogawa, Hiroaki Shimokawa, Irina Veze, Birute Petrauskiene, Leon Salvador, Jan Hein Cornel, Tor Ole Klemsdal, Felix Medina, Andrzej Budaj, Luminita Vida-Simiti, Zhanna Kobalava, Petar Otasevic, Daniel Pella, Mitja Lainscak, Ki-Bae Seung, Patrick Commerford, Mikael Dellborg, Marc Donath, Juey-Jen Hwang, Hakan Kultursay, Marcus Flather, Christie Ballantyne, Seth Bilazarian, William Chang, Cara East, Les Forgosh, Barry Harris, Monica Ligueros
Journal: The Lancet (2017)